These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 10969778)
1. Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model. Yokoyama Y; Green JE; Sukhatme VP; Ramakrishnan S Cancer Res; 2000 Aug; 60(16):4362-5. PubMed ID: 10969778 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Calvo A; Yokoyama Y; Smith LE; Ali I; Shih SC; Feldman AL; Libutti SK; Sundaram R; Green JE Int J Cancer; 2002 Sep; 101(3):224-34. PubMed ID: 12209972 [TBL] [Abstract][Full Text] [Related]
3. VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis. Wild R; Yokoyama Y; Dings RP; Ramakrishnan S Breast Cancer Res Treat; 2004 May; 85(2):161-71. PubMed ID: 15111774 [TBL] [Abstract][Full Text] [Related]
4. Mouse hunt. Gawande A Minn Med; 1998 Aug; 81(8):10-2. PubMed ID: 9715627 [No Abstract] [Full Text] [Related]
5. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Montico F; Kido LA; Hetzl AC; Cagnon VH Prostate; 2015 Apr; 75(5):484-99. PubMed ID: 25521760 [TBL] [Abstract][Full Text] [Related]
6. Effect of endostatin on 1,2-dimethylhydrazine-induced colon tumor in mice. Karaca O; Ertekin T; Canoz O; Ulger H; Soysal H; Kus I Toxicol Ind Health; 2012 Feb; 28(1):21-6. PubMed ID: 21505005 [TBL] [Abstract][Full Text] [Related]
7. First clinical trials of endostatin yield lukewarm results. Twombly R J Natl Cancer Inst; 2002 Oct; 94(20):1520-1. PubMed ID: 12381701 [No Abstract] [Full Text] [Related]
8. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Kim YM; Jang JW; Lee OH; Yeon J; Choi EY; Kim KW; Lee ST; Kwon YG Cancer Res; 2000 Oct; 60(19):5410-3. PubMed ID: 11034081 [TBL] [Abstract][Full Text] [Related]
9. Soluble recombinant endostatin purified from Escherichia coli: antiangiogenic activity and antitumor effect. Huang X; Wong MK; Zhao Q; Zhu Z; Wang KZ; Huang N; Ye C; Gorelik E; Li M Cancer Res; 2001 Jan; 61(2):478-81. PubMed ID: 11212235 [TBL] [Abstract][Full Text] [Related]
10. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Yokoyama Y; Dhanabal M; Griffioen AW; Sukhatme VP; Ramakrishnan S Cancer Res; 2000 Apr; 60(8):2190-6. PubMed ID: 10786683 [TBL] [Abstract][Full Text] [Related]
11. The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. Berger AC; Feldman AL; Gnant MF; Kruger EA; Sim BK; Hewitt S; Figg WD; Alexander HR; Libutti SK J Surg Res; 2000 Jun; 91(1):26-31. PubMed ID: 10816345 [TBL] [Abstract][Full Text] [Related]
12. Expression and purification of human endostatin in Pichia pastoris and its inhibition on the growth of mouse pulmonary adenocarcinoma cell line LA795. Xia H; Zhang L; Wen JX; Tong WC Di Yi Jun Yi Da Xue Xue Bao; 2002 May; 22(5):393-6. PubMed ID: 12390693 [TBL] [Abstract][Full Text] [Related]
13. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model. Plum SM; Hanson AD; Volker KM; Vu HA; Sim BK; Fogler WE; Fortier AH Clin Cancer Res; 2003 Oct; 9(12):4619-26. PubMed ID: 14555538 [TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Perletti G; Concari P; Giardini R; Marras E; Piccinini F; Folkman J; Chen L Cancer Res; 2000 Apr; 60(7):1793-6. PubMed ID: 10766159 [TBL] [Abstract][Full Text] [Related]
15. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Dhanabal M; Ramchandran R; Volk R; Stillman IE; Lombardo M; Iruela-Arispe ML; Simons M; Sukhatme VP Cancer Res; 1999 Jan; 59(1):189-97. PubMed ID: 9892206 [TBL] [Abstract][Full Text] [Related]
16. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206 [TBL] [Abstract][Full Text] [Related]
17. N-/C-terminal deleted mutant of human endostatin efficiently acts as an anti-angiogenic and anti-tumorigenic agent. Cho H; Kim WJ; Lee YM; Kim YM; Kwon YG; Park YS; Choi EY; Kim KW Oncol Rep; 2004 Jan; 11(1):191-5. PubMed ID: 14654925 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of microregional variations in tumor hypoxia following the administration of endostatin. Fenton BM; Paoni SF; Beauchamp BK; Tran B; Liang L; Grimwood B; Ding I Adv Exp Med Biol; 2003; 510():19-24. PubMed ID: 12580399 [No Abstract] [Full Text] [Related]
19. Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. Ding I; Sun JZ; Fenton B; Liu WM; Kimsely P; Okunieff P; Min W Cancer Res; 2001 Jan; 61(2):526-31. PubMed ID: 11212245 [TBL] [Abstract][Full Text] [Related]
20. Disparate effects of endostatin on tumor vascular perfusion and hypoxia in two murine mammary carcinomas. Fenton BM; Paoni SF; Grimwood BG; Ding I Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1038-46. PubMed ID: 14575835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]